부산대학교 도서관

Cemiplimab is currently the only immune checkpoint inhibitor treatment approved for advanced cutaneous squamous cell carcinoma (CSCC).1,2 While other programmed cell death protein-1 (PD-1) antibodies are treatment options for advanced or metastatic non-small cell lung cancer (NSCLC), the use of cemiplimab is still under study for this cancer3 and has not received formal approval. At the end of first month, lesions located on the right cervical region and scalp were treated with radiotherapy to control local bleeding (3D conformal radiation therapy, 12 Gy delivered in two fractions/lesion). A control PET performed after 4 months of treatment showed a significant metabolic regression of the left pulmonary and right clavicle lesions, as well as most facial and scalp lesions (Figure 2D-F). [Extracted from the article]